Skip to main
ASTH

ASTH Stock Forecast & Price Target

ASTH Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Astrana Health is positioned for success due to its strong partnerships, efficient coding and technology, and expected increase in Medicare reimbursement. However, competition, potential setbacks from Medicaid, and risks associated with full-risk conversion may impact the company's growth in the future.

Bears say

Astrana Health is in the healthcare industry in the United States and operates in an attractive market of value-based care, providing coordinated, outcomes-based medical care for patients with multiple chronic conditions. However, the company faces risks with its reliance on a few key segments for the majority of its revenue, potential increases in healthcare costs, and uncertain regulatory and political landscapes. Furthermore, ASTH may face significant upfront costs and challenges with implementing new clients and integrating acquired businesses. These factors, combined with the company's young age and significant losses, contribute to a negative outlook on the stock.

ASTH has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Astrana Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Astrana Health Inc (ASTH) Forecast

Analysts have given ASTH a Strong Buy based on their latest research and market trends.

According to 7 analysts, ASTH has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Astrana Health Inc (ASTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.